title: Childhood refractory autoimmune haemolytic anaemia: is there a role for anti-CD20 therapy (rituximab)?
authors.forename: C
authors.initials: C
authors.lastname: McMahon
authors.forename: L
authors.initials: L
authors.lastname: Babu
authors.forename: A
authors.initials: A
authors.lastname: Hodgson
authors.forename: A
authors.initials: A
authors.lastname: Hayat
authors.forename: N O
authors.initials: NO
authors.lastname: Connell
authors.forename: O P
authors.initials: OP
authors.lastname: Smith
mesh_terms: D000293:Adolescent; D000744:Anemia, Hemolytic, Autoimmune / Q000276:immunology / Q000628:therapy*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001402:B-Lymphocytes / Q000276:immunology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007166:Immunosuppressive Agents; D000069283:Rituximab